SYNERGISTIC CANCER TREATMENT

Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides...

Full description

Saved in:
Bibliographic Details
Main Authors FONTAINE Shaun, SANTI Daniel V
Format Patent
LanguageEnglish
Spanish
Published 29.05.2023
Subjects
CHEMISTRY
COMPOSITIONS BASED THEREON
HUMAN NECESSITIES
HYGIENE
MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVINGCARBON-TO-CARBON UNSATURATED BONDS
MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES
MEDICAL OR VETERINARY SCIENCE
METALLURGY
NANOTECHNOLOGY
ORGANIC MACROMOLECULAR COMPOUNDS
PERFORMING OPERATIONS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES
THEIR PREPARATION OR CHEMICAL WORKING-UP
TRANSPORTING
Online AccessGet full text

Cover

More Information
Summary:Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects. Conjugados de inhibidores de topoisomerasa I enlazados a una macromolécula a través de un enlace que se somete a eliminación beta in situ en combinación con uno o más de un defecto estimado en la respuesta de daño de ADN (DDR) en un sujeto portador de cáncer, un inhibidor de punto de control del ciclo celular y/o un inhibidor DDR proporciona efectos mejorados para sujetos portadores de cáncer.
Bibliography:Application Number: MX2023005786